A systematic review was conducted. Nine electronic databases and trial registries were searched up to the end of July 2018. Studies were eligible for inclusion if they were randomized controlled trials (RCT) in a population at risk of osteoporotic fracture, comparing these four non-bisphosphonates DEN, RLX, ROMO, or TPTD with each other, a non-active treatment, or the bisphosphonates alendronate (ALN), risedronate (RIS), ibandronate (IBN) and zoledronic acid (ZOL). Quality of included studies was assessed using the Cochrane Risk of Bias tool. Network meta-analyses (NMA) were used to determine the relative effectiveness of treatments.
The four non-bisphosphonate interventions studied were all statistically significantly clinically effective for reducing vertebral fractures when compared to placebo, and were beneficial for change in FN BMD compared to placebo. All reduced hip fractures, and this was statistically significant for TPTD, ROMO followed by ALN, and DEN.
Editorial: Journal of Health and Medical Research
Young Research Forum: Journal of Health and Medical Research
Young Research Forum: Journal of Health and Medical Research
Awards 2021: Journal of Health and Medical Research
Awards 2021: Journal of Health and Medical Research
Editorial: Journal of Health and Medical Research
Posters & Accepted Abstracts: Oncology & Cancer Case Reports
Posters & Accepted Abstracts: Oncology & Cancer Case Reports
Scientific Tracks Abstracts: Oncology & Cancer Case Reports
Scientific Tracks Abstracts: Oncology & Cancer Case Reports
Keynote: Oncology & Cancer Case Reports
Keynote: Oncology & Cancer Case Reports
Keynote: Oncology & Cancer Case Reports